Core Insights - Investors in Edwards Lifesciences Corporation should monitor stock movements due to high implied volatility in the options market, particularly the Nov. 21, 2025 $50 Put option [1] Company Overview - Edwards Lifesciences is currently rated as Zacks Rank 3 (Hold) in the Medical – Instruments industry, which ranks in the top 37% of the Zacks Industry Rank [3] - Over the last 60 days, seven analysts have raised their earnings estimates for the current quarter, resulting in an increase of the Zacks Consensus Estimate from 59 cents per share to 61 cents [3] Market Sentiment - The high implied volatility suggests that options traders are anticipating significant price movement for Edwards Lifesciences shares, indicating potential trading opportunities [4] - Seasoned options traders often seek high implied volatility options to sell premium, aiming for the underlying stock to not move as much as expected at expiration [4]